Connection

Laurent Peyrin-Biroulet to Male

This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Male.
Connection Strength

0.224
  1. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018 Nov 09; 12(10):1180-1190.
    View in: PubMed
    Score: 0.011
  2. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis. 2019 02; 51(2):236-241.
    View in: PubMed
    Score: 0.011
  3. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. Dig Liver Dis. 2019 01; 51(1):112-119.
    View in: PubMed
    Score: 0.011
  4. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. Dig Liver Dis. 2018 10; 50(10):1012-1018.
    View in: PubMed
    Score: 0.011
  5. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018 Apr; 47(7):906-912.
    View in: PubMed
    Score: 0.010
  6. TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice. J Crohns Colitis. 2018 Jan 24; 12(2):230-244.
    View in: PubMed
    Score: 0.010
  7. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783.
    View in: PubMed
    Score: 0.010
  8. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
    View in: PubMed
    Score: 0.010
  9. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
    View in: PubMed
    Score: 0.010
  10. Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
    View in: PubMed
    Score: 0.010
  11. Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2017 03; 23(3):333-340.
    View in: PubMed
    Score: 0.010
  12. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017 Mar; 49(3):280-285.
    View in: PubMed
    Score: 0.009
  13. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut. 2012 Jan; 61(1):78-85.
    View in: PubMed
    Score: 0.007
  14. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
    View in: PubMed
    Score: 0.003
  15. Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
    View in: PubMed
    Score: 0.003
  16. Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
    View in: PubMed
    Score: 0.003
  17. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
    View in: PubMed
    Score: 0.003
  18. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
    View in: PubMed
    Score: 0.003
  19. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 02; 17(3):494-501.
    View in: PubMed
    Score: 0.003
  20. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther. 2018 10; 48(8):831-838.
    View in: PubMed
    Score: 0.003
  21. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168.
    View in: PubMed
    Score: 0.003
  22. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis. 2018 10; 50(10):1019-1029.
    View in: PubMed
    Score: 0.003
  23. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Aliment Pharmacol Ther. 2018 06; 47(12):1652-1660.
    View in: PubMed
    Score: 0.003
  24. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study. Dig Liver Dis. 2018 Sep; 50(9):903-909.
    View in: PubMed
    Score: 0.003
  25. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22.
    View in: PubMed
    Score: 0.003
  26. Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflamm Bowel Dis. 2018 03 19; 24(4):766-774.
    View in: PubMed
    Score: 0.003
  27. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Dig Liver Dis. 2018 07; 50(7):668-674.
    View in: PubMed
    Score: 0.003
  28. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar; 33(3):664-670.
    View in: PubMed
    Score: 0.003
  29. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):316-322.
    View in: PubMed
    Score: 0.003
  30. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018 03; 47(5):588-595.
    View in: PubMed
    Score: 0.003
  31. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 04; 154(5):1343-1351.e1.
    View in: PubMed
    Score: 0.003
  32. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Dig Liver Dis. 2018 Jun; 50(6):563-567.
    View in: PubMed
    Score: 0.003
  33. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2018 06; 16(6):892-899.e2.
    View in: PubMed
    Score: 0.003
  34. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
    View in: PubMed
    Score: 0.003
  35. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis. 2017 11; 23(11):2048-2053.
    View in: PubMed
    Score: 0.003
  36. Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2017 Oct 27; 11(11):1347-1352.
    View in: PubMed
    Score: 0.002
  37. Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. J Crohns Colitis. 2017 Oct 27; 11(11):1326-1334.
    View in: PubMed
    Score: 0.002
  38. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27; 11(11):1317-1325.
    View in: PubMed
    Score: 0.002
  39. Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. PLoS One. 2017; 12(9):e0184624.
    View in: PubMed
    Score: 0.002
  40. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
    View in: PubMed
    Score: 0.002
  41. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents. Am J Gastroenterol. 2018 02; 113(2):265-272.
    View in: PubMed
    Score: 0.002
  42. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 08; 23(8):1425-1433.
    View in: PubMed
    Score: 0.002
  43. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
    View in: PubMed
    Score: 0.002
  44. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017 08; 46(3):310-321.
    View in: PubMed
    Score: 0.002
  45. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. J Crohns Colitis. 2017 May 01; 11(5):519-526.
    View in: PubMed
    Score: 0.002
  46. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017 07; 46(2):142-149.
    View in: PubMed
    Score: 0.002
  47. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
    View in: PubMed
    Score: 0.002
  48. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. Inflamm Bowel Dis. 2017 01; 23(1):126-132.
    View in: PubMed
    Score: 0.002
  49. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596.
    View in: PubMed
    Score: 0.002
  50. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013 Dec; 62(12):1714-23.
    View in: PubMed
    Score: 0.002
  51. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9601-6.
    View in: PubMed
    Score: 0.002
  52. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol. 2008 Dec; 103(12):3115-22.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.